Adagene Unveils Data At SITC Highlighting Enhanced Therapeutic Index And Safety For Masked Anti-CTLA-4 SAFEbody ADG126, Showing Efficacy As Monotherapy And In Combination With Anti-PD-1 In Advanced MSS Colorectal Cancer
Adagene Unveils Data At SITC Highlighting Enhanced Therapeutic Index And Safety For Masked Anti-CTLA-4 SAFEbody ADG126, Showing Efficacy As Monotherapy And In Combination With Anti-PD-1 In Advanced MSS Colorectal Cancer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.